Colchicine Shows Promise Against Moderate and Severe COVID-19
Researchers evaluated the effect of adjuvant colchicine with standard therapy among patients with moderate and severe COVID-19 infection.
Researchers evaluated the effect of adjuvant colchicine with standard therapy among patients with moderate and severe COVID-19 infection.
In this ninth update to the living guideline on COVID-19 therapeutics, the World Health Organization evaluates the use of nirmatrelvir/ritonavir for nonsevere COVID-19 and revises prior recommendations regarding the use of remdesivir.
Graham M. Snyder, MD, MS, provides further insight into a study that evaluated the effects of an early return-to-work program that reduced the quarantine period for clinicians who remained asymptomatic after exposure to COVID-19.